SGLT2i may provide further nephro-cardioprotection in LN through their antiproteinuric effects, in addition to background therapy with ACE inhibitors or sartans, but their role in LN must still be defined [249], as previously discussed. The gene discussed is ACE; the disease is lobular neoplasia.